Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants

Journal of Virology

Volumn 87, Issue 12, 2013, Pages 6569-6581

  Berro, Reem ^a   Yasmeen, Anila ^a   Abrol, Ravinder ^c,e   Trzaskowski, Bartosz ^d   Abi Habib, Sarya ^a   Grunbeck, Amy ^b   Lascano, Danny ^a   Goddard III , William A ^c   Klasse, Per Johan ^a   Sakmar, Thomas P ^b   Moore, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF WARSAW   (Poland)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; PERTUSSIS TOXIN; PROTEIN VARIANT; VICRIVIROC;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA SEQUENCE; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR AFFINITY; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; VIRUS INHIBITION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GTP-BINDING PROTEINS; HEK293 CELLS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PERTUSSIS TOXIN; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; TRANSFECTION; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878557177     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00099-13     Document Type: Article

References (61)

1. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
2. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. 1996. CD4- dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 384:184-187.
3. Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK, Zolla-Pazner S, Littman DR. 1997. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. J. Virol. 71:6296-6304.
4. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
5. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD. 2007. Structures of the CCR5 N terminus and of a tyrosinesulfated antibody with HIV-1 gp120 and CD4. Science 317:1930-1934.
6. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP, Dragic T. 2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77:5201-5208.
7. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP. 2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A. 97:5639-5644.
8. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM, Moore JP. 2004. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 78:2790-2807.
9. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.
10. Berro R, Klasse PJ, Jakobsen MR, Gorry PR, Moore JP, Sanders RW. 2012. V3 determinants of HIV-1 escape from the CCR5 inhibitors maraviroc and vicriviroc. Virology 427:158-165.
11. Yao XJ, Velez Ruiz G, Whorton MR, Rasmussen SG, DeVree BT, Deupi X, Sunahara RK, Kobilka B. 2009. The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc. Natl. Acad. Sci. U. S. A. 106:9501-9506.
12. Ye S, Zaitseva E, Caltabiano G, Schertler GF, Sakmar TP, Deupi X, Vogel R. 2010. Tracking G-protein-coupled receptor activation using genetically encoded infrared probes. Nature 464:1386-1389.
13. Brady AE, Limbird LE. 2002. G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell Signal. 14:297-309.
14. Hepler JR, Gilman AG. 1992. G proteins. Trends Biochem. Sci. 17:383-387.
15. Kaslow HR, Burns DL. 1992. Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J. 6:2684-2690.
16. Wu Y, Yoder A. 2009. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PLoS Pathog. 5:e1000520. doi:10.1371/journal.ppat.1000520.
17. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2:1244-1247.
18. Farzan M, Choe H, Martin KA, Sun Y, Sidelko M, Mackay CR, Gerard NP, Sodroski J, Gerard C. 1997. HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5. J. Biol. Chem. 272:6854-6857.
19. Amara A, Vidy A, Boulla G, Mollier K, Garcia-Perez J, Alcami J, Blanpain C, Parmentier M, Virelizier JL, Charneau P, Arenzana- Seisdedos F. 2003. G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. J. Virol. 77:2550-2558.
20. Yoder A, Yu D, Dong L, Iyer SR, Xu X, Kelly J, Liu J, Wang W, Vorster PJ, Agulto L, Stephany DA, Cooper JN, Marsh JW, Wu Y. 2008. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 134:782-792.
21. Harmon B, Ratner L. 2008. Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry. J. Virol. 82:9191-9205.
22. Harmon B, Campbell N, Ratner L. 2010. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step. PLoS Pathog. 6:e1000956. doi:10.1371/journal.ppat.1000956.
23. Wang W, Guo J, Yu D, Vorster PJ, Chen W, Wu Y. 2012. A dichotomy in cortical actin and chemotactic actin activity between human memory and naive T cells contributes to their differential susceptibility to HIV-1 infection. J. Biol. Chem. 287:35455-35469.
24. Berro R, Klasse PJ, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP. 2011. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors. J. Virol. 85:8227-8240.
25. Garcia-Perez J, Rueda P, Staropoli I, Kellenberger E, Alcami J, Arenzana-Seisdedos F, Lagane B. 2011. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J. Biol. Chem. 286:4978-4990.
26. Alvarez Arias D, Navenot JM, Zhang WB, Broach J, Peiper SC. 2003. Constitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2. J. Biol. Chem. 278:36513-36521.
27. Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, Tagat JR, Clader JW, McCombie SW, Baroudy BM, Smith SO, Dragic T, Moore JP, Sakmar TP. 2006. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349:41-54.
28. Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP. 2009. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 5:e1000548. doi:10.1371/journal.ppat.1000548.
29. Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP. 2009. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 106:5318-5323.
30. Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP. 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338:182-199.
31. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
32. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF, 3rd, Burton DR, Ho DD. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
33. Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. 2011. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J. Biol. Chem. 286:32188-32197.
34. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE. 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361:212-228.
35. Moore JP, Kuritzkes DR. 2009. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 4:118-124.
36. Ogert RA, Wojcik L, Buontempo C, Ba L, Buontempo P, Ralston R, Strizki J, Howe JA. 2008. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373: 387-399.
37. Mangmool S, Kurose H. 2011. G(i/o) protein-dependent and -independent actions of pertussis toxin (PTX). Toxins (Basel) 3:884-899.
38. Alfano M, Schmidtmayerova H, Amella CA, Pushkarsky T, Bukrinsky M. 1999. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. J. Exp. Med. 190: 597-605.
39. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H. 1990. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(pbromocinnamylamino) ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J. Biol. Chem. 265:5267-5272.
40. Lagane B, Ballet S, Planchenault T, Balabanian K, Le Poul E, Blanpain C, Percherancier Y, Staropoli I, Vassart G, Oppermann M, Parmentier M, Bachelerie F. 2005. Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. Mol. Pharmacol. 67:1966-1976.
41. Mettling C, Desmetz C, Fiser AL, Reant B, Corbeau P, Lin YL. 2008. Galphai protein-dependent extracellular signal-regulated kinase-1/2 activation is required for HIV-1 reverse transcription. AIDS 22:1569-1576.
42. Marozsan AJ, Torre VS, Johnson M, Ball SC, Cross JV, Templeton DJ, Quinones-Mateu ME, Offord RE, Arts EJ. 2001. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. J. Virol. 75:8624-8638.
43. Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF, Ray N, Jeffrey JL, Labranche CC, Doms RW. 2010. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res. Hum. Retroviruses 26:13-24.
44. Abrol R, Griffith AR, Bray JK, Goddard WA, 3rd. 2012. Structure prediction of G protein-coupled receptors and their ensemble of functionally important conformations. Methods Mol. Biol. 914:237-254.
45. Labrecque J, Metz M, Lau G, Darkes MC, Wong RS, Bogucki D, Carpenter B, Chen G, Li T, Nan S, Schols D, Bridger GJ, Fricker SP, Skerlj RT. 2011. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a highthroughput assay. Virology 413:231-243.
46. Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M. 2008. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73:789-800.
47. Grunbeck A, Huber T, Abrol R, Trzaskowski B, Goddard WA, 3rd, Sakmar TP. 2012. Genetically encoded photo-cross-linkers map the binding site of an allosteric drug on a G protein-coupled receptor. ACS Chem. Biol. 7:967-972.
48. Billick E, Seibert C, Pugach P, Ketas T, Trkola A, Endres MJ, Murgolo NJ, Coates E, Reyes GR, Baroudy BM, Sakmar TP, Moore JP, Kuhmann SE. 2004. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J. Virol. 78:4134-4144.
49. Govaerts C, Blanpain C, Deupi X, Ballet S, Ballesteros JA, Wodak SJ, Vassart G, Pardo L, Parmentier M. 2001. The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokineinduced activation. J. Biol. Chem. 276:13217-13225.
50. Govaerts C, Bondue A, Springael JY, Olivella M, Deupi X, Le Poul E, Wodak SJ, Parmentier M, Pardo L, Blanpain C. 2003. Activation of CCR5 by chemokines involves an aromatic cluster between transmembrane helices 2 and 3. J. Biol. Chem. 278:1892-1903.
51. de Voux A, Chan MC, Folefoc AT, Madziva MT, Flanagan CA. 2013. Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion. PLoS One 8:e54532. doi:10.1371/journal.pone.0054532.
52. Gonsiorek W, Strizki JM, Hesk D, Lundell D, Hipkin RW. 2006. Analysis of CCR5 binding kinetics and coupling states reveals distinctive binding properties of small molecule CCR5 antagonists, as reported by Levin J. 46th Intersci. Conf. Antimicrob. Agents Chemother., 27 to 30 September 2006. http://www.natap.org/2006/ICAAC/ICAAC_57.htm.
53. Tuosto L, Parolini I, Schroder S, Sargiacomo M, Lanzavecchia A, Viola A. 2001. Organization of plasma membrane functional rafts upon T cell activation. Eur. J. Immunol. 31:345-349.
54. Cardaba CM, Kerr JS, Mueller A. 2008. CCR5 internalisation and signalling have different dependence on membrane lipid raft integrity. Cell Signal. 20:1687-1694.
55. Zhang ZQ, Wietgrefe SW, Li Q, Shore MD, Duan L, Reilly C, Lifson JD, Haase AT. 2004. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. U. S. A. 101:5640-5645.
56. Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee FH, Didigu CA, Berro R, Klasse PJ, Lee B, Moore JP, Shaw GM, Hahn BH, Doms RW. 2013. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J. Virol. 87:2401-2411.
57. Ping L-H, Joseph SB, Anderson JA, Abrahams M-R, Salazar-Gonzalez JF, Kincer LP, Treurnicht FK, Arney L, Ojeda S, Zhang M, Keys J, Potter EL, Chu H, Moore P, Salazar-Gonzalez M, Iyer S, Jabara C, Kirchherr J, Mapanje C, Ngandu N, Seoighe C, Hoffman I, Gao F, Tang Y, Labranche C, Lee B, Saville A, Vermeulen M, Fiscus S, Morris L, Karim SA, Haynes BF, Shaw GM, Korber BT, Hahn BH, Cohen MS, Montefiori D, Williamson C, Swanstrom R. 24 April 2013. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J. Virol. doi:10.1128/JVI.03577-12.
58. Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, Moore JP. 2005. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat. Med. 11:1293-1294.
59. Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP. 2010. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J. Infect. Dis. 202:739-744.
60. Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, Doyle LA, Rasmussen KK, Goldman L, Ketas TJ, Moore JP. 2012. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob. Agents Chemother. 56:2251-2258.
61. Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Klasse PJ, Moore JP. 2013. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J. Antimicrob. Chemother. 68: 678-683.